A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen

Journal of Applied Toxicology

Volumn 26, Issue 1, 2006, Pages 72-80

  Irwin, Richard D ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

butyrolactone; hydroxybutyric acid; 1,4 butanediol; Carcinogenicity; Metabolism

Indexed keywords

1,4 BUTANEDIOL; 4 HYDROXYBUTYRIC ACID; CARCINOGEN; GAMMA BUTYROLACTONE; SUCCINIC ACID;

ACUTE TOXICITY; BLOOD BRAIN BARRIER; CARCINOGENICITY; CHRONIC TOXICITY; CITRIC ACID CYCLE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSFORMATION; GENOTOXICITY; HUMAN; LD 50; NEUROPHARMACOLOGY; NONHUMAN; PHEOCHROMOCYTOMA; PREDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

4-BUTYROLACTONE; ANIMALS; BIOTRANSFORMATION; BUTYLENE GLYCOLS; CARCINOGENICITY TESTS; HUMANS; HYDROXYBUTYRATES; SOLVENTS;

ANIMALIA;

EID: 31644438171     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1110     Document Type: Review

References (70)

1. Adornato BT, Tse V. 1992. Another health food hazard: γ-hydroxybutyrate-induced seizures. West. J. Med. 157: 471.
2. Arena C, Fung HL. 1980. Absorption of sodium γ-hydroxybutyrate and its prodrug γ-butyrolactone: Relation between in vitro transport and in vivo absorption. J. Pharm. Sci. 69: 356-358.
3. Bergleson LD, Vaver VA, Prokazova NV, Ushakov AN, Popkova GA. 1966. Diol lipids. Biochem. Biophys. Acta 116: 511-520.
4. Bessman SP, McCabe RB. 1972. 1,4-Butanediol - A substrate for rat liver and horse liver alcohol dehydrogenases. Biochem. Pharmacol. 21: 1135-1142.
5. Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Minardi G, Gess L. 2001. Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur. J. Pharmacol. 428(3): 315-321.
6. Carai MA, Colombo G, Reali R, Serra S, Mocci I, Castelli MP, Cignarella G, Gessa GL. 2002. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur. J. Pharmacol. 441(3): 157-163.
7. Cash C. 1994. Gamma-hydroxybutyrate: An overview of the pros and cons for it being a neurotransmitter and/or useful theraputic agent. Neurosci. Behav. Rev. 18: 291-302.
8. Chemical Economics Handbook. Stanford Research Institute, Menlo Park, CA, Section 621.5030.
9. Dyer JE. 1991. Gamma-hydroxybutyrate: A health-food product producing coma and seizure like activity. Am. J. Emerg. Med. 9: 321-324.
10. Fadda F, Mosca E, Colombo G, Gessa GL. 1989. Suppression by gamma-hydroxybutyric acid of ethanol withdrawl syndrome in rats. Alcohol Alcohol. 24: 447-451.
11. Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, Gessa GL, Palatini P. 1992. Pharmacokinetics of γ-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br. J. Clin. Pharmacol. 34: 231-235.
12. Fishbein WN, Bessman SP. 1966. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of γ-lactones. J. Biol. Chem. 241: 4835-4844.
13. GAF Corporation; Summary of Toxicity Information for 1,4-Butanediol. Pamphlet No. 201-628-3000.
14. Giarman NJ, Roth RH. 1964. Differential estimation of gamma-butyrolactone and gamma-hydroxybutyric acid in rat blood and brain. Science 145: 583-584.
15. Gibson KM, Sweetman L, Nyhan WL, Jakobs C, Rating D, Siemes H, Hanefeld F. 1983. Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clin. Chim. Acta 133: 33-42.
16. Godschalk M, Dzoljic MR, Bonta IL. 1977. Slow wave sleep and a state resembling absence epilepsy induced in the rat by hydroxybutyrate. Eur. J. Pharmacol. 44: 105-111.
17. HAZARDOUS SUBSTANCES DATA BASE (HSDB), National Library of Medicine Toxicology Data Network (TOXNET).
18. Hechler V, Goballie S, Maitre M. 1992. Selective distribution pattern of γ-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res. 572: 345-348.
19. Hunter AS, Long WJ, Ryrie CG. 1971. An evaluation of gamma-hydroxy butyric acid in paediatric practice. Br. J. Anaesthesiol. 43: 620-628.
20. Jakobs C, Bojasch M, Monch E, Rating D, Siemse H, Hanefeld F. 1981. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin. Chim. Acta 111: 169-178.
21. Japan Ministry of Health and Welfare. 1997. Toxicity testing reports of environmental chemicals 5: 429-442.
22. Japan Ministry of Health and Welfare. 1999. Toxicity testing reports of environmental chemicals 7: 371-385.
23. Jedrychowski R, Stetkiewicz J, Stetkiewicz I. 1990a. Acute toxicity of 1,4-butanediol in laboratory animals. Polish J. Occup. Med. 3: 415-420.
24. Jedrychowski RA, Gorny R, Stetkiewicz J, Stetkiewicz I. 1990b. Subacute oral toxicity of 1,4-butanediol in rats. Polish J. Occup. Med. 3: 421-427.
25. Kaufman E, Nelson T. 1981. Kinetics of coupled γ-hydroxybutyrate oxidation and D-glucuronate reduction by an NADP-dependent oxidoreductase. J. Biol. Chem. 256: 6890-6894.
26. +-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem. Res. 16: 965-974.
27. Kinney LA, Burgess BA, Stula EF, Kennedy GL. 1985. Acute and subchronic inhalation toxicity of 1,4-butanediol in rats. The Toxicologist 5: 130, abstract 520.
28. Kinney LA, Burgess BA, Stula EF, Kennedy GL. 1991. Acute and subchronic inhalation toxicity of 1,4-butanediol in rats. Inhal. Toxicol. 3: 379-388.
29. Kirk-Othmer 1978. Encyclopedia of Chemical Technology. 3rd edn, vol. 1. John Wiley & Sons: New York.
30. Lettieri J, Fung HL. 1978. Improved pharmacological activity via pro drug modification: Comparative pharmacokinetics of sodium hydroxybutyrate and γ-butyrolactone. Res. Commun. Chem. Pathol. 22: 107-118.
31. Mack RB. 1993. Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. N. C. Med. J. 54: 232-233.
32. Maitre M. 1997. The γ-hydroxybutyrate signalling system in brain: organization and functional implications. Progr. Neurobiol. 51: 337-361.
33. Maitre M, Andriamampandry C, Kemmel V, Schmidt C, Hode Y, Hechler V, Gobaille S. 2000. Gammhydroxybutyric acid as a signalling molecule in brain. Alcohol 20: 277-283.
34. Maitre M, Cash C, Weissman-Nanopoulos D, Mandel P. 1983. Depolarization evoked release of γ-hydroxybutyrate from rat brain slices. J. Neurochem. 41: 287-290.
35. Mamelak M, Scharf MB, Woods M. 1986. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9: 285-289.
36. Mandel P, Maitre M, Vayer P, Hechler V. 1987. Function of gamma hydroxybutyrate: a putative neurotransmitter. Biochem. Soc. Trans. 15: 215-217.
37. Material Safety Data Sheet. 1985. 1,4-Butanediol. G485. Genium Publishing Corporation: Schenectady, NY.
38. Maxwell R, Roth RH. 1972. Conversion of 1,4-butanediol to hydroxybutyric acid in rat brain and in peripheral tissue. Biochem. Pharmacol. 21: 1521-1533.
39. National Occupational Hazard Survey (1972-1974). 1976. National Institute for Occupational Safety and Health: Cincinnati, OH.
40. National Occupational Exposure Survey (1980-1983). 1984. National Institute for Occupational Safety and Health: Cincinnati, OH.
41. 1 mice. NIH Publication No. 92-3137.
42. National Toxicology Program (NTP). 1989. Project report: Absorption, disposition, metabolism and excretion of 1,4-butanediol in rats after oral administration.
43. National Toxicology Program (NTP). 1996. Summary report on the metabolism, disposition, and toxicity of 1,4-butanediol. NIH Publication 96-3932.
44. Osuide G. 1972. Effects of gamma-hydroxybutyrate on chick behavior, electrocortical activity, and crossed extensor reflexes. Br. J. Pharmacol. 44: 593.
45. Poldrugo F, Snead OC. 1986. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 3: 367-370.
46. Price CJ, Marr MC, Myers CB, Heindel JJ, Schweiz BA. 1993. Developmental toxicity evaluation of 1,4-butanediol (BUTE) in swiss mice. Teratology 47: 433.
47. Quang LS, Shannon MW, Woolf AD, Desai MC, Maher TJ. 2002. Pretreatment of CD-I mice with 4-methylpyrazole blocks toxicity from the gamma-hydroxybutyrate precursor, 1,4-butanediol. Life Sci. 71: 771-778.
48. Roth RH. 1970. Formation and regional distribution γ-hydroxybutyric acid in mammalian brain. Biochem. Pharmacol. 19: 3013-3018.
49. Roth RH, Giarman NJ. 1965. Preliminary report on the metabolism of γ-butyrolactone and γ-hydroxybutyric acid. Biochem. Pharmacol. 14: 177-178.
50. Roth R, Giarman NJ. 1966. γ-Butyrolactone and γ- hydroxybutyric acid I. Distribution and metabolism. Biochem. Pharmacol. 15: 1333-1348.
51. Roth RH, Giarman NJ. 1968. Evidence that central nervous system depression by 1,4-butanediol is mediated through a metabolite, gamma hydroxybutyrate. Biochem. Pharmacol. 17: 735-739.
52. Roth RH, Delgado JMR, Giarman NJ. 1966. γ-Butyrolactone and γ-hydroxybutyric acid II. The pharmacologically active form. Int. J. Neuropharmacol. 5: 421-428.
53. Rumigny JF, Maitre M, Cash C, Mandel P. 1981. Regional and subcellular localization in rat brain of the enzymes that can synthesize γ-hydroxybutyric acid. J. Neurochem. 36: 1433-1438.
54. Scala RA, Paynter OE. 1967. Chronic oral toxicity of 1,4-butanediol. Toxicol. Appl. Pharmacol. 10: 160-164.
55. Snead OC. 1988. γ-Hydroxybutyrate model of generalized absence seizures: Further characterization and comparison with other absence models. Epilepsia 29: 361-368.
56. Snead OC. 1991. The γ-hydroxybutyrate model of absence seizures: correlation of regional brain levels of γ-hydroxybutyric acid and γ-butyrolactone with spike wave discharges. Neuropharmacology 30: 161-167.
57. Snead OC. 1992. Pharmacological models of generalized absence seizures in rodents. J. Neural. Transm. (Suppl) 35: 7-19.
58. Snead OC, Furner R, Liu CC. 1989. In vivo conversion of γ-aminobutyric acid and 1,4-butanediol to γ-hydroxybutyric acid in rat brain. Biochem. Pharmacol. 38: 4375-4380.
59. Sprince H, Josephs JA, Wilpizeski CR. 1966. Neuropharmacological effects of 1,4-butanediol and related congeners compared with those of gamma hydroxybutyrate and gamma-butyrolactone. Life Sci. 5: 2041-2052.
60. Taberner PV, Pearce MJ. 1974. Hypothermic and toxic actions of 2-butyne 1,4-diol and other related diols. J. Pharm. Pharmacol. 26: 597-604.
61. Van-Bemmelen FJ, Schouten MJ, Fekkes D, Bruinvels J. 1985. Succinic semialdehyde as a substrate for the formation of gamma-aminobutyric acid. J. Neurochem. 45: 1471-1474.
62. Van der Pol W, Van der Kleign E, Lauw M. 1975. Gas chromatographic determination and pharmacokinetics of 4-hydroxybutyrate in dog and mouse. J. Pharmacokinet. Biopharm. 3: 99-113.
63. Vayer P, Mandel P, Maitre M. 1985. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J. Neurochem. 45: 810-814.
64. Vayer P, Mandel P, Maitre M. 1987. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci. 44: 1547-1557.
65. Vree TB, Van Dalen R, van der Kleijn, Gimbrere JSF. 1978. Pharmacokinetics of butanediol 1,4 and 4-hydroxybutyric acid in man, rhesus monkey, and dog. Anaesthesiol. Intensivmed. 110: 66-73.
66. Winters WD, Spooner CE. 1965. A neurophysiological comparison of gamma-hydroxybutyrate with pentobarbital in cats. Electroenceph. Clin. Neurophysiol. 18: 287.
67. Yamada YJ, Yamamoto A, Fujiki A, Hishikawa Y, Kaneko Z. 1967. Effect of butyrolactone and gamma-hydroxybutyrate on the EEG and sleep cycle in man. Electronenceph. Clin. Neurophysiol. 22: 558.
68. Zabic JE, Van Dam DP, Maickel RP. 1974. Pharmacological and toxicological studies on 1,4-butanediol. Res. Commun. Chem. Pathol. Pharmacol. 8: 83-90.
69. Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelman K. 1992. Salmonella mutagenicity tests V. Results from the testing of 311 chemicals. Environ. Mol. Mut. 19 (suppl 21): 2-141.
70. Zvosec DL, Smith SW, McCutheon R, Spillane J, Hall BJ, Peacock EA. 2001. Adverse events including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. 344: 87-94.